NRx Pharma Achieves Data-lock In Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study

Biopharmaceutical company NRx Pharmaceuticals, Inc. (NRXP) announced Monday that it has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101.

Related Keywords

,Alvogen Inc ,Lotus Pharmaceuticals Inc ,Nrx Pharmaceuticals Inc ,Treatment Resistant Bipolar Depression Study ,Lotus Pharmaceuticals ,Breakthrough Therapy Designation ,Fast Track Designation ,Biomarker Letter ,Special Protocol Agreement ,Suicidal Treatment Resistant Bipolar ,